Prostate cancer, version 2.2014.

No abstract is available for this paper.

• Publication year

  2014

• Venue

  The Journal of the National Comprehensive Cancer Network

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  PMID 24812137
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A proposal of a new nomogram for predicting upstaging in contemporary D’Amico low-risk prostate cancer patients

  2017cited by this paper
• Clinical Outcomes and Survival Following Treatment of Metastatic Castrate-Refractory Prostate Cancer With Docetaxel Alone or With Strontium-89, Zoledronic Acid, or Both: The TRAPEZE Randomized Clinical Trial.

  2016cited by this paper
• Increased Risk for Other Cancers in Addition to Breast Cancer for CHEK2*1100delC Heterozygotes Estimated From the Copenhagen General Population Study.

  2016cited by this paper
• Family History and Probability of Prostate Cancer, Differentiated by Risk Category: A Nationwide Population-Based Study.

  2016cited by this paper
• Prognostic Utility of a New mRNA Expression Signature of Gleason Score

  2016cited by this paper
• Severe neutropenia during cabazitaxel treatment is associated with survival benefit in men with metastatic castration-resistant prostate cancer (mCRPC): A post-hoc analysis of the TROPIC phase III trial.

  2016cited by this paper
• Enzalutamide Versus Bicalutamide in Castration-Resistant Prostate Cancer: The STRIVE Trial.

  2016cited by this paper
• Predicting survival of men with recurrent prostate cancer after radical prostatectomy.

  2016cited by this paper
• Mismatch repair deficiency may be common in ductal adenocarcinoma of the prostate

  2016cited by this paper
• Anti-tumour activity of platinum compounds in advanced prostate cancer-a systematic literature review.

  2016cited by this paper
• Recent Trends in PSA Testing and Prostate Cancer Incidence: A Look at Context.

  2016cited by this paper
• Occult High-risk Disease in Clinically Low-risk Prostate Cancer with ≥50% Positive Biopsy Cores: Should National Guidelines Stop Calling Them Low Risk?

  2016cited by this paper
• A Contemporary Prostate Cancer Grading System: A Validated Alternative to the Gleason Score.

  2016cited by this paper
• Biallelic Inactivation of BRCA2 in Platinum-sensitive Metastatic Castration-resistant Prostate Cancer.

  2016cited by this paper
• Efficacy and safety of enzalutamide versus bicalutamide for patients with metastatic prostate cancer (TERRAIN): a randomised, double-blind, phase 2 study.

  2016cited by this paper
• Current Status of Prostate Cancer Diagnosis and Management in the United States.

  2016cited by this paper
• Development and validation of a 24-gene predictor of response to postoperative radiotherapy in prostate cancer: a matched, retrospective analysis.

  2016cited by this paper
• Tissue-based Genomics Augments Post-prostatectomy Risk Stratification in a Natural History Cohort of Intermediate- and High-Risk Men.

  2016cited by this paper
• Early evidence of anti-PD-1 activity in enzalutamide-resistant prostate cancer

  2016cited by this paper
• The Ongoing Challenges of Targeting the Androgen Receptor.

  2016cited by this paper
• Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer.

  2016cited by this paper
• Analytic Validation of a Clinical-Grade PTEN Immunohistochemistry Assay in Prostate Cancer by Comparison to PTEN FISH

  2016cited by this paper
• Validation of the Kattan Nomogram for Prostate Cancer Recurrence After Radical Prostatectomy.

  2016cited by this paper
• Patient-specific Meta-analysis of 2 Clinical Validation Studies to Predict Pathologic Outcomes in Prostate Cancer Using the 17-Gene Genomic Prostate Score.

  2016cited by this paper
• Evaluation of the 2015 Gleason Grade Groups in a Nationwide Population-based Cohort.

  2016cited by this paper
• The AVOCAT study: Bicalutamide monotherapy versus combined bicalutamide plus dutasteride therapy for patients with locally advanced or metastatic carcinoma of the prostate—a long-term follow-up comparison and quality of life analysis

  2016cited by this paper
• Differences in Prostate-Specific Antigen Testing Among Urologists and Primary Care Physicians Following the 2012 USPSTF Recommendations.

  2016cited by this paper
• Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation.

  2015cited by this paper
• Cancers associated with BRCA1 and BRCA2 mutations other than breast and ovarian

  2015cited by this paper
• Evaluation of models predicting insignificant prostate cancer to select men for active surveillance of prostate cancer

  2015cited by this paper
• National Prostate Cancer Screening Rates After the 2012 US Preventive Services Task Force Recommendation Discouraging Prostate-Specific Antigen-Based Screening.

  2015cited by this paper
• Integrative clinical genomics of advanced prostate cancer.

  2015cited by this paper
• Definition and Validation of "Favorable High-Risk Prostate Cancer": Implications for Personalizing Treatment of Radiation-Managed Patients.

  2015cited by this paper
• Nadir testosterone within first year of androgen-deprivation therapy (ADT) predicts for time to castration-resistant progression: a secondary analysis of the PR-7 trial of intermittent versus continuous ADT.

  2015cited by this paper
• Prostate-Specific Antigen Screening After 2012 US Preventive Services Task Force Recommendations.

  2015cited by this paper
• DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer.

  2015cited by this paper
• Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial.

  2015cited by this paper
• Contemporary Nationwide Patterns of Active Surveillance Use for Prostate Cancer.

  2015cited by this paper
• Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer.

  2015cited by this paper
• Characterization of 1577 primary prostate cancers reveals novel biological and clinicopathologic insights into molecular subtypes.

  2015cited by this paper
• Validation of International Society of Urological Pathology (ISUP) grading for prostatic adenocarcinoma in thin core biopsies using TROG 03.04 ‘RADAR’ trial clinical data

  2015cited by this paper
• Combined value of validated clinical and genomic risk stratification tools for predicting prostate cancer mortality in a high-risk prostatectomy cohort.

  2015cited by this paper
• Prostate Cancer Incidence and PSA Testing Patterns in Relation to USPSTF Screening Recommendations.

  2015cited by this paper
• A Biopsy-based 17-gene Genomic Prostate Score Predicts Recurrence After Radical Prostatectomy and Adverse Surgical Pathology in a Racially Diverse Population of Men with Clinically Low- and Intermediate-risk Prostate Cancer.

  2015cited by this paper
• Incidence and Predictors of Upgrading and Up Staging among 10,000 Contemporary Patients with Low Risk Prostate Cancer.

  2015cited by this paper
• Validation of an RNA cell cycle progression score for predicting death from prostate cancer in a conservatively managed needle biopsy cohort

  2015cited by this paper
• Annual Report to the Nation on the Status of Cancer, 1975-2011, Featuring Incidence of Breast Cancer Subtypes by Race/Ethnicity, Poverty, and State

  2015cited by this paper
• The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma: Definition of Grading Patterns and Proposal for a New Grading System

  2015cited by this paper
• Loss-of-function variants in ATM confer risk of gastric cancer

  2015cited by this paper
• Novel Biomarker Signature That May Predict Aggressive Disease in African American Men With Prostate Cancer.

  2015cited by this paper
• Effect of BRCA Mutations on Metastatic Relapse and Cause-specific Survival After Radical Treatment for Localised Prostate Cancer.

  2015cited by this paper
• Recent decline in prostate cancer incidence in the United States, by age, stage, and Gleason score

  2015influential reference
• A genomic classifier improves prediction of metastatic disease within 5 years after surgery in node-negative high-risk prostate cancer patients managed by radical prostatectomy without adjuvant therapy.

  2015cited by this paper
• Patient-derived xenografts reveal that intraductal carcinoma of the prostate is a prominent pathology in BRCA2 mutation carriers with prostate cancer and correlates with poor prognosis.

  2015cited by this paper
• Effect of the USPSTF Grade D Recommendation against Screening for Prostate Cancer on Incident Prostate Cancer Diagnoses in the United States.

  2015cited by this paper
• Prostate cancer incidence in males with Lynch syndrome

  2014cited by this paper
• Implementing the use of nomograms by choosing threshold points in predictive models: 2012 updated Partin Tables vs a European predictive nomogram for organ‐confined disease in prostate cancer

  2014cited by this paper
• RNA biomarkers associated with metastatic progression in prostate cancer: a multi-institutional high-throughput analysis of SChLAP1.

  2014cited by this paper
• Cardiovascular morbidity associated with gonadotropin releasing hormone agonists and an antagonist.

  2014cited by this paper
• Enzalutamide in metastatic prostate cancer before chemotherapy.

  2014cited by this paper
• Cancer statistics, 2014

  2014cited by this paper
• Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: results of CALGB 90202 (alliance).

  2014cited by this paper
• Diethylstilboestrol for the treatment of prostate cancer: past, present and future

  2014cited by this paper
• Genomic Prostate Cancer Classifier Predicts Biochemical Failure and Metastases in Patients After Postoperative Radiation Therapy

  2014cited by this paper
• Incidence of complications other than urinary incontinence or erectile dysfunction after radical prostatectomy or radiotherapy for prostate cancer: a population-based cohort study.

  2014cited by this paper
• Prognostic utility of the cell cycle progression score generated from biopsy in men treated with prostatectomy.

  2014cited by this paper
• Effectiveness of primary androgen-deprivation therapy for clinically localized prostate cancer.

  2014cited by this paper
• Effect of enzalutamide on time to first skeletal-related event, pain, and quality of life in men with castration-resistant prostate cancer: results from the randomised, phase 3 AFFIRM trial.

  2014cited by this paper
• Predicting survival of patients with node-positive prostate cancer following multimodal treatment.

  2014cited by this paper
• PTEN Loss is Associated with Upgrading of Prostate Cancer from Biopsy to Radical Prostatectomy

  2014cited by this paper
• Risk of Prostate Cancer in Lynch Syndrome: A Systematic Review and Meta-analysis

  2014cited by this paper
• Multi-institutional validation of the CAPRA-S score to predict disease recurrence and mortality after radical prostatectomy.

  2014cited by this paper
• Fifteen-year survival outcomes following primary androgen-deprivation therapy for localized prostate cancer.

  2014cited by this paper
• Comparative effectiveness of external-beam radiation approaches for prostate cancer.

  2014cited by this paper
• Prostate cancer risk prediction based on complete prostate cancer family history

  2014cited by this paper
• Morbidity of focal therapy in the treatment of localized prostate cancer.

  2013cited by this paper
• Ki-67 is an independent predictor of metastasis and cause-specific mortality for prostate cancer patients treated on Radiation Therapy Oncology Group (RTOG) 94-08.

  2013cited by this paper
• Abiraterone in metastatic prostate cancer without previous chemotherapy.

  2013cited by this paper
• Prognostic value of Ki-67 for prostate cancer death in a conservatively managed cohort

  2013cited by this paper
• Proton versus intensity-modulated radiotherapy for prostate cancer: patterns of care and early toxicity.

  2013cited by this paper
• Stereotactic body radiotherapy for localized prostate cancer: disease control and quality of life at 6 years

  2013cited by this paper
• Cardiovascular outcomes in patients with locally advanced and metastatic prostate cancer treated with luteinising-hormone-releasing-hormone agonists or transdermal oestrogen: the randomised, phase 2 MRC PATCH trial (PR09)

  2013cited by this paper
• OMICS-based personalized oncology: if it is worth doing, it is worth doing well!

  2013cited by this paper
• A genomic classifier predicting metastatic disease progression in men with biochemical recurrence after prostatectomy

  2013cited by this paper
• Stereotactic body radiotherapy for localized prostate cancer: pooled analysis from a multi-institutional consortium of prospective phase II trials.

  2013cited by this paper
• Long-term functional outcomes after treatment for localized prostate cancer.

  2013cited by this paper
• Stereotactic Body Radiation Therapy (SBRT) for clinically localized prostate cancer: the Georgetown University experience

  2013cited by this paper
• Discovery and Validation of a Prostate Cancer Genomic Classifier that Predicts Early Metastasis Following Radical Prostatectomy

  2013cited by this paper
• A new risk classification system for therapeutic decision making with intermediate-risk prostate cancer patients undergoing dose-escalated external-beam radiation therapy.

  2013cited by this paper
• Randomized trial of hypofractionated external-beam radiotherapy for prostate cancer.

  2013cited by this paper
• Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer.

  2013cited by this paper
• From genome to bedside: are we lost in translation?

  2013cited by this paper
• Prognostic utility of cell cycle progression score in men with prostate cancer after primary external beam radiation therapy.

  2013cited by this paper
• Validation of a cell-cycle progression gene panel to improve risk stratification in a contemporary prostatectomy cohort.

  2013cited by this paper
• African American men with very low-risk prostate cancer exhibit adverse oncologic outcomes after radical prostatectomy: should active surveillance still be an option for them?

  2013cited by this paper
• Impact of cabazitaxel on 2-year survival and palliation of tumour-related pain in men with metastatic castration-resistant prostate cancer treated in the TROPIC trial

  2013cited by this paper
• Use of advanced treatment technologies among men at low risk of dying from prostate cancer.

  2013cited by this paper
• Validation of a genomic classifier that predicts metastasis following radical prostatectomy in an at risk patient population.

  2013cited by this paper
• An evidence based review of proton beam therapy: the report of ASTRO's emerging technology committee.

  2012cited by this paper
• Systematic review and meta-analysis of studies reporting potency rates after robot-assisted radical prostatectomy.

  2012cited by this paper

• Socioeconomic Disparities in Prostate Cancer Presentation: The Impact of ADI on Prostate Cancer Stage at Diagnosis.

  2025cites this paper
• Prediction of metastasis-free survival in patients with localized prostate adenocarcinoma using primary tumor and lymph node radiomics from pre-treatment PSMA-PET/CT scans

  2025cites this paper
• Opportunistic screening for osteoporosis and vertebral fracture using CT attenuation from 18F-fluorocholine PET/CT in patients with prostate cancer

  2025cites this paper
• Radical prostatectomy is associated with favorable outcomes in patients over 80 years old.

  2025cites this paper
• Racial and ethnic differences in valuation of life expectancy in prostate cancer treatment decision making.

  2025cites this paper
• Evaluation of prostate cancer detection using micro-ultrasound versus MRI through co-registration to whole-mount pathology

  2024cites this paper
• Early change in apparent diffusion coefficient as a predictor of response to neoadjuvant androgen deprivation and external beam radiation therapy for intermediate- to high-risk prostate cancer.

  2024cites this paper
• Trends in pre-biopsy MRI usage for prostate cancer detection, 2007–2022

  2024cites this paper
• Germline sequence variation in cancer genes in Rwandan breast and prostate cancer cases

  2024cites this paper
• De-escalation in DCIS Care

  2023cites this paper
• Primary Total Prostate Cryoablation for Localized High-Risk Prostate Cancer: 10-Year Outcomes and Nomograms

  2023cites this paper
• Management and health-related quality of life among patients with prostate cancer in a Kenyan tertiary health facility

  2023cites this paper
• Using active surveillance for Gleason 7 (3+4) prostate cancer: A narrative review.

  2023influential citation
• The role of multiparametric magnetic resonance in active surveillance of a low‐risk prostate cancer cohort from clinical practice

  2023cites this paper
• Revisiting current National Comprehensive Cancer Network (NCCN) high-risk prostate cancer stratification: a National Cancer Database analysis

  2023cites this paper
• A prospective study of the prostate health index density and multiparametric magnetic resonance imaging in diagnosing clinically significant prostate cancer

  2023cites this paper
• External Validation of a Prognostic Model Predicting Metastatic Castration-Resistant Prostate Cancer Survival in Patients Receiving Post-Docetaxel Second-Line Chemotherapy

  2022influential citation
• Đánh giá bước đầu kết quả phẫu thuật nội soi qua phúc mạc cắt toàn bộ tuyến tiền liệt điều trị bệnh lý ung thư tuyến tiền liệt

  2022cites this paper
• Identification of a Steroid Hormone-Associated Gene Signature Predicting the Prognosis of Prostate Cancer through an Integrative Bioinformatics Analysis

  2022cites this paper
• Whole-body MRI in oncology: can a single anatomic T2 Dixon sequence replace the combination of T1 and STIR sequences to detect skeletal metastasis and myeloma?

  2022cites this paper
• Gnetin C Intercepts MTA1-Associated Neoplastic Progression in Prostate Cancer

  2022cites this paper
• Validation of models predicting lymph node involvement probability in patients with prostate cancer

  2022cites this paper
• Approach to the Treatment of Metastatic Castration-Sensitive Prostate Carcinoma: A Single Center Experience

  2022cites this paper
• Perioperative Morbidity of Radical Prostatectomy After Intensive Neoadjuvant Androgen Blockade in Men With High-Risk Prostate Cancer: Results of Phase II Trial Compared to a Control Group.

  2022cites this paper
• Assessment of androgen receptor signaling inhibitors therapy in metastatic hormone-sensitive prostate cancer

  2022cites this paper
• US lesion visibility predicts clinically significant upgrade of prostate cancer by systematic biopsy

  2022cites this paper
• Radiation treatment in prostate cancer: covering the waterfront

  2021cites this paper
• Three-dimensional nuclear magnetic resonance spectroscopy: a complementary tool to multiparametric magnetic resonance imaging in the identification of aggressive prostate cancer at 3.0T.

  2021cites this paper
• Chemotherapy with atezolizumab for small cell or neuroendocrine carcinoma of the prostate: A single institution experience

  2021cites this paper
• Risk of Fracture During Androgen Deprivation Therapy Among Patients With Prostate Cancer: A Systematic Review and Meta-Analysis of Cohort Studies

  2021cites this paper
• Comparative performance of MRI-derived PRECISE scores and delta-radiomics models for the prediction of prostate cancer progression in patients on active surveillance

  2021cites this paper
• Facility-Level Variation in Use of Locoregional Therapy for Metastatic Prostate Cancer

  2021cites this paper
• OTT_A_315170 4819..4832

  2021cites this paper
• Association between the polygenic liabilities for prostate cancer and breast cancer with biochemical recurrence after radical prostatectomy for localized prostate cancer.

  2021cites this paper
• 68Ga‐prostate‐specific membrane antigen (PSMA) PET/CT as a clinical decision‐making tool in biochemically recurrent prostate cancer

  2021cites this paper
• IVIM–DKI for differentiation between prostate cancer and benign prostatic hyperplasia: comparison of 1.5 T vs. 3 T MRI

  2021influential citation
• Proteomic discovery of non-invasive biomarkers of localized prostate cancer using mass spectrometry

  2021cites this paper
• Active Surveillance in Prostate Cancer: Role of Available Biomarkers in Daily Practice

  2021cites this paper
• A Recursive Partitioning Analysis Demonstrating Risk Subsets for 8-Year Biochemical Relapse After Margin-Positive Radical Prostatectomy Without Adjuvant Hormone or Radiation Therapy

  2021cites this paper
• Long-Term Outcomes of Whole Gland Salvage Cryotherapy for Locally Recurrent Prostate Cancer following Radiation Therapy: A Combined Analysis of Two Centers

  2021cites this paper
• The one hundred most cited publications in prostate brachytherapy.

  2021cites this paper
• Familiäres Prostatakarzinom und genetische Prädisposition

  2021cites this paper
• Polygenic risk score for genetic evaluation of prostate cancer risk in Asian populations: A narrative review

  2021cites this paper
• PSA and PSA Kinetics as Predictors for 18F-Fluciclovine PET/CT Positivity in Biochemically Recurrent Prostate Cancer

  2021cites this paper
• A review on the role of tissue-based molecular biomarkers for active surveillance

  2021cites this paper
• Comparison of Diffusion Kurtosis Imaging and Amide Proton Transfer Imaging in the Diagnosis and Risk Assessment of Prostate Cancer

  2021cites this paper
• Implementing Continuous Quality Improvement in an Integrated Community Urology Practice: Lessons Learned.

  2021cites this paper
• Prostate Cancer Disparities in Risk Group at Presentation and Access to Treatment for Asian Americans, Native Hawaiians, and Pacific Islanders: A Study With Disaggregated Ethnic Groups

  2021cites this paper
• SEOM clinical guidelines for the treatment of advanced prostate cancer (2020)

  2021cites this paper
• Immune Checkpoint Inhibitors in Prostate Cancer

  2021cites this paper
• Multi-criteria optimization for planning volumetric-modulated arc therapy for prostate cancer

  2021cites this paper
• Inhibitors of the PI3K/Akt/mTOR Pathway in Prostate Cancer Chemoprevention and Intervention

  2021cites this paper
• Survival after Radical Prostatectomy versus Radiation Therapy in High-Risk and Very High-Risk Prostate Cancer

  2021cites this paper
• Ga-prostate specific membrane antigen (

  2021cites this paper
• Clinical Utility of Olaparib in the Treatment of Metastatic Castration-Resistant Prostate Cancer: A Review of Current Evidence and Patient Selection

  2021cites this paper
• Patient assessment of lower urinary tract symptoms using the international prostate symptom score following low-dose-rate prostate brachytherapy.

  2021cites this paper
• Interaction between race and prostate cancer treatment benefit in the Veterans Health Administration

  2021cites this paper
• The efficacy and tolerability of ultra-hypofractionated radiotherapy in low-intermediate risk prostate cancer patients: single center experience

  2021cites this paper
• Treatment Pattern and Outcomes with Systemic Therapy in Men with Metastatic Prostate Cancer in the Real-World Patients in the United States

  2021cites this paper
• Urinary proteomic profiles of prostate cancer with different risk of progression and correlation with histopathological features.

  2021cites this paper
• The gut microbiota associated with high‐Gleason prostate cancer

  2021cites this paper
• Lower Urinary Tract Symptoms in Prostate Cancer Patients Treated With Radiation Therapy: Past and Present

  2021cites this paper
• Trimodal treatment for localized high-risk prostate cancer: A design of a phase II, multi-center, open-label, randomized, parallel-group study to compare the effectiveness and safety of trimodal treatment for patients with localized high-risk prostate cancer.

  2020cites this paper
• Dosimetric comparison of fixed field dynamic IMRT and VMAT techniques in simultaneous integrated boost radiotherapy of prostate cancer

  2020cites this paper
• Three-dimensional Camera Systems Assistant the Sheath of Prostate Preservation Laparoscopic Radical Prostatectomy: Technique and Initial Experience

  2020cites this paper
• SLX4IP Promotes Telomere Maintenance in Androgen Receptor–Independent Castration-Resistant Prostate Cancer through ALT-like Telomeric PML Localization

  2020cites this paper
• Diagnostic Yield of Incremental Biopsy Cores and Second Lesion Sampling for In-Gantry MRI-Guided Prostate Biopsy.

  2020cites this paper
• Implementation and Impact of a Risk-Stratified Prostate Cancer Screening Algorithm as a Clinical Decision Support Tool in a Primary Care Network

  2020cites this paper
• Clinical Evaluation of (4S)-4-(3-[18F]Fluoropropyl)-L-glutamate (18F-FSPG) for PET/CT Imaging in Patients with Newly Diagnosed and Recurrent Prostate Cancer

  2020cites this paper
• Association between prostate cancer characteristics and BRCA1/2-associated family cancer history in a Japanese cohort

  2020cites this paper
• Magnetic resonance imaging of the prostate after focal therapy with high-intensity focused ultrasound

  2020cites this paper
• Biomarkers in the setting of benign prostatic HyperplasiaInduced lower urinary tract symptoms: What an interventional radiologist needs toKnow.

  2020cites this paper
• Intermediate Risk Prostate Cancer: Disease Heterogeneity Linked to Measurable Biological Features.

  2020cites this paper
• High‐dose‐rate brachytherapy and hypofractionated external beam radiotherapy combined with long‐term androgen deprivation therapy for very high‐risk prostate cancer

  2020cites this paper
• Osteoporosis screening using computed tomography for men with prostate cancer: results of a prospective study

  2020cites this paper
• Magnetic Resonance Imaging Assessment After Therapy in Prostate Cancer.

  2020cites this paper
• Evaluation of apparent diffusion coefficient as a predictor of grade reclassification in men on active surveillance for prostate cancer.

  2020cites this paper
• Poly(ADP-Ribose) Polymerase Inhibitors in Prostate Cancer: Molecular Mechanisms, and Preclinical and Clinical Data

  2020cites this paper
• [Indications and outlooks of radiohormonal therapy of high-risk prostate cancers].

  2020cites this paper
• Might definitive local therapy of the primary tumor improve the survival benefits of metastatic prostate cancer? -evidence from a meta-analysis.

  2020cites this paper
• Circulating Tumor Cells as a Predictor of Treatment Response in Clinically Localized Prostate Cancer.

  2019cites this paper
• Variation in Positive Surgical Margin Status After Radical Prostatectomy for pT2 Prostate Cancer.

  2019cites this paper
• Appraising causal relationships of dietary, nutritional and physical-activity exposures with overall and aggressive prostate cancer: two-sample Mendelian randomization study based on 79,148 prostate cancer cases and 61,106 controls

  2019cites this paper
• Active Surveillance for Low-Risk Prostate Cancer in Black Patients.

  2019cites this paper
• Gallium-68 prostate-specific membrane antigen PET-CT and the clinical management of prostate cancer.

  2019cites this paper
• The current landscape of low-value care in men diagnosed with prostate cancer: what is the role of individual hospitals?

  2019cites this paper
• Localised Prostate Versus Whole Pelvic Irradiation in High Risk Prostate Cancer, Single Institute Experience

  2019cites this paper
• Variation in positive surgical margin status following radical prostatectomy for pT2 prostate cancer

  2019cites this paper
• Tumor characteristics, oncological and functional outcomes after radical prostatectomy in very young men ≤ 45 years of age

  2019cites this paper
• NES1/KLK10 and hNIS gene therapy enhanced iodine-131 internal radiation in PC3 proliferation inhibition

  2019cites this paper
• [Optimizing local control of high-risk prostate cancers through multimodal treatments].

  2019cites this paper
• Clinical Impact of Lower-Limb Imaging in 68Ga-PSMA PET/CT for Patients with Prostate Cancer

  2019cites this paper
• Management of advanced prostate cancer: A systematic review of existing guidelines and recommendations.

  2019cites this paper
• Is active surveillance an appropriate approach to manage prostate cancer patients with Gleason Score 3+3 who met the criteria for active surveillance?

  2019cites this paper
• Focal Laser Ablation of Prostate Cancer: Results in 120 Patients with Low- to Intermediate-Risk Disease.

  2019cites this paper
• Downregulation of serum CXCL4L1 predicts progression and poor prognosis in prostate cancer patients treated by radical prostatectomy

  2019cites this paper
• Integrity of the Urethral Sphincter Complex, Nerve-sparing, and Long-term Continence Status after Robotic-assisted Radical Prostatectomy.

  2019cites this paper
• Management of urethral stricture due to prostate cancer and colorectal cancer radiotherapy: a systematic review

  2019cites this paper
• Ten-Year Results From a Phase II Study on Image Guided, Intensity Modulated Radiation Therapy With Simultaneous Integrated Boost in High-Risk Prostate Cancer

  2019cites this paper
• Henry Ford Health System

  2019cites this paper